Uncategorized


January 9, 2026

Conference Policy Prep Pack: Medtech & Biopharma

By John Leppard

With medtech and biopharma companies set to descend on San Francisco next week, below we provide a set of significant policy-related questions for clients to ask management, the answers to which will inform company growth…

Read More >>

January 8, 2026

INSP: MAC Feedback Points to Lower Doc & Facility Rates

By John Leppard

Following repeated outreach to Medicare Administrative Contractor (MAC) public inquiry mailboxes, feedback from WPS – responsible for ~13% of INSP services – bolsters our view that the company is unlikely to be able to take…

Read More >>

January 7, 2026

Tariffs on Trial: Assessing the Supreme Court’s IEEPA Decision

By Joe Lieber

Consistent with our prior note, we continue to assign 60%-65% odds that the Trump administration suffers at least a partial loss in the International Emergency Economic Powers Act (IEEPA) case currently pending before the Supreme Court (SCOTUS). Importantly, the Court…

Read More >>

January 6, 2026

Health Insurers & Providers Outstanding Policy Issues During 1Q26

By Beth Steindecker

With the start of the new year and holdover of some key issues from 2025, 1Q26 promises various policy catalysts across the health insurer and provider landscapes, informing company growth and revenue prospects for the…

Read More >>

December 30, 2025

INSP: How The MAC Tides Have Turned

By John Leppard

With Medicare Administrative Contractor (MAC) WPS – responsible for ~13% of INSP claims – now joining Noridian (17%), NGS (9%), and CGS (6%) in removing cranial nerve code 64568 from its hypoglossal obstructive sleep apnea…

Read More >>

December 29, 2025

Obesity Model & “Deal” Demo Exclusions

By John Leppard

CMS’s BALANCE Model to facilitate coverage of anti-obesity medications (AOMs) [LLY, NVO] in Medicaid and Medicare Part D (PD) (standalone and Medicare Advantage plans) – released Dec. 23 – while still lacking key details, provides…

Read More >>

December 21, 2025

Rx Model Risks: So Much For “Deals”

By John Leppard

CMS’s mandatory Medicare Part D (here) / Part B (here) international drug pricing model proposals released Friday suggest that – besides an ostensible reprieve from as yet unrealized tariffs – recent drug manufacturer “deals” with…

Read More >>

December 18, 2025

INSP: More MAC Confusion

By John Leppard

Despite this morning’s billing article updates from Medicare Administrative Contractors (MACs) Noridian [here] and CGS [here] – removing CPT 64568 from the list of covered codes for hypoglossal nerve stimulation (HGNS) for obstructive sleep apnea…

Read More >>

December 18, 2025

Sports Betting: State Tax Update

By Joe Lieber

As we enter 2026, we highlight the following four states that we believe are the most likely candidates to at least consider raising their online sports betting tax for DraftKings (DKNG), Flutter’s FanDuel (FLUT), MGM…

Read More >>